Denise Wolleschak1, Florian H Heidel2. Show Affiliations » 1. Otto-von-Guericke University Medical Center Magdeburg. 2. University Hospital Jena.
Abstract
Entities: Disease
Mesh: See more » Antineoplastic Agents/therapeutic useBone Marrow/drug effectsBone Marrow/pathologyBortezomib/therapeutic useDexamethasone/therapeutic useFemaleHumansImatinib Mesylate/therapeutic useLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapyLeukemia, Myelogenous, Chronic, BCR-ABL Positive/etiologyLeukemia, Myelogenous, Chronic, BCR-ABL Positive/pathologyMiddle AgedMultiple Myeloma/complicationsMultiple Myeloma/drug therapyMultiple Myeloma/pathology
Substances: See more » Antineoplastic AgentsBortezomibDexamethasoneImatinib Mesylate
Year: 2016 PMID: 28092869 DOI: 10.1182/blood-2016-03-706945
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113